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The COVID-19 pandemic has triggered a worldwide suspension of all fertility treatments 
following national and international guidance. In response to the direct threat of COVID-19 to 
patients, the wider Scottish population and NHS Scotland services, all NHS funded Scottish 
centres took the decision collectively not to start any new treatments after 17th March 2020. 
Those already in middle of their treatment, had their embryos frozen to avoid pregnancy. This 
was to reduce non-essential treatments and associated travel during the lockdown period. It 
also released staff and other resources from the fertility sector to COVID-related areas. 
There was uncertainty of the effect of COVID on pregnancy and pregnancy on susceptibility 
of COVID infection. This complied with HFEA`s General Direction (GD0014)1. 
 
While stopping of all treatments happened very quickly, restart is anticipated to be more 
complex, specifically due to safety measures required for staff and patients in clinic. Although 
not considered urgent services similar to oncology, fertility treatments are extremely time 
sensitive with increase in female age being the single most important factor determining the 
success rates. The Scottish Government has been exemplary in funding fertility services and 
it is important that these services are provided in a timely manner to be effective and cost 
effective. 
 





2 Principles of Restarting Fertility treatment  
 
Prior to re-introduction of fertility treatment, clinics must formulate a robust and measured 
plan to resume services which will ensure safe and effective treatment in combination with 
minimising patient and staff risk of Covid-19.  This is an unprecedented situation and there is 
limited literature to guide a restart strategy. Hence, we will use guidance issued by the 
professional bodies (ESHRE & BFS/ARCS)2,3, regulatory authority (HFEA)4, public health 
and Government5. We will also learn from experiences of colleagues in other countries who 
are ahead of UK in this pandemic 6 and take in consideration of risks in pregnancy7.  
 
At all times any decision about fertility treatments will ensure that critical requirements are 
met as advised by HFEA (Table 1 & 3), abide by principles laid down by the First Minister5 
(Table 2) and professional bodies (Table 4) in the framework for decision making in relation 
to COVID-19.  
 
Table 1: Criteria in critical decision making (as per HFEA letter to PR on 23/04/20)1 
 
 That Government restrictions on social contact and travel are lifted or eased 
 That restarting fertility treatment would not have a negative impact on the NHS 
 That there was no evidence that Covid-19 impacted on the health of pregnant women 
or their babies* 
 That fertility clinics are able to provide a safe service 
* There is further evidence to when this document was released. 
 
 






Table 3: Criteria for opening up clinics (as per HFEA letter to PR on 01/05/2020) 4 
 
 Record the measures that the centre will be taking to comply with current guidance on 
safe and effective treatment and the mitigating actions taken in relation to each risk; 
 Record the risk assessments undertaken by the centre to identify risks arising from 
the provision of treatment and the mitigating actions in relation to each risk; 
 Record the practical and logistical measures the centre will be taking to deliver 
treatment safely and in a manner that mitigates the risks arising from, or associated 
with, Covid-19 for both patients and staff; 
 Record all new or revised standard operating procedures or protocols which have 
been developed to enable treatment to resume safely whilst maintaining compliance 




Table 4: Five key principles (outlined in BFS /ARCS document released on 06/05/2020)3 
 
 Resumption of fertility services must take place in a manner that minimises the 
chances of spread of COVID-19 infection to patients and fertility clinic staff. 
 Centres should ensure a fair and transparent approach to any prioritisation policy. 
 Resumption of treatment should not result in an undue burden on the NHS. 
 Patients considering treatment should be fully informed about the effect of the 
ongoing pandemic on their treatment and give informed consent to having fertility 
treatment at this time. 
 The fertility sector should adopt sustainable changes in working practices that help to 








3 Planning for restarting fertility treatment  
 
 
3.1 Capacity Planning 
 
Fertility Services rely on multidisciplinary and cross-directorate collaboration in order to 
provide safe and effective treatment which is compliant with the European directive and UK 
regulation. Prior to resumption of fertility treatment, a detailed capacity analysis will be 
required involving early engagement with key stakeholders to identify service level decision 
makers within areas such as anaesthetics8, diagnostics, virology, microbiology, biochemistry 
and genetics to ensure that they can support the third-party testing and turn-around times 
required to provide treatment. Provision of fertility treatment also relies on other services 
such as routine cervical screening services which are currently suspended.  
It is also important to engage with referral pathways to predict estimated numbers of 
referrals. This will include dialogue with referring Health Boards as well as GP services, wider 
acute services including Urology, Endocrinology, Gender Identity Service and Oncology. 
Clinics may experience an initial reduction in pre-pandemic numbers due to ongoing social 
distancing measures. However, as social distancing measures are eased and referral 
pathways resume to normal service, it is reasonable to assume that the numbers of patients 
accessing the service will increase. It will be important to estimate the impact on waiting 
times in order for patients to be appropriately informed as soon as it is logistically possible. 
The key driver in capacity planning will be the number of treatment cycles and the split of 
treatment types which can be safely processed through the laboratory area while observing 
safe social distancing practices. Once the laboratory capacity has been determined, the flow 
of patients entering treatment and all associated appointments can be appropriately planned 
and clinic templates devised. This planning will be critical in accurately forecasting waiting 
times and preventing bottlenecks and hidden waiting lists. 
  
3.2 Modifications to practices  
 
In order to meet the principles laid out in section 2, several practices will need to be modified 
to ensure safety.  The following modifications were collectively agreed in meetings on 
28/04/20 and 05/05/2020. 
 
Increased use of remote consultations 
Most consultations (medical, nursing, laboratory and counselling) will be remote using 
systems e.g. attend anywhere, near me. This will ensure that whatever can be done without 
a face to face appointment is done prior to patients attending in person. It will significantly 
reduce the number of face to face appointments, hospital attendances and staff-patient 
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contact time, thereby increasing patient and staff safety. Hence everyone will have remote 
consultation prior to attendance in person.  
 
Telephone screening check immediately prior to attending clinic  
Telephone consultations to patients a day prior to attending clinic for appointment (e.g. for 
semen analysis, ultrasound scan, tubal patency check) to check if all immediate pre- test 
requirements are met (e.g. contraception for tubal patency check & abstinence for semen 
analysis) to reduce risk of cancelling on the day.  In addition, this will ensure patients are still 
asymptomatic from COVID-19. This will avoid unnecessary travel. 
 
Restricted access to clinics 
Most fertility treatments involve couples.  Traditionally we have encouraged both partners to 
attend. However, we would advise restriction for partners to attend unless there was absolute 
clinical need to do so. This is to ensure footfall is reduced as well as risk of transmission. 
 
Access criteria for treatments  
Currently smoking and BMI are access criteria for treatments, and they have traditionally 
been checked (by carbon monoxide testing and taking height and weight in clinics) at face to 
face appointments. It was collectively agreed (28/04/20) that this can be done by asking 
patients in remote consultations. This will be checked and documented opportunistically at 
the first face to face appointment and patients will only progress with treatment if the eligibility 
criteria are met. Patients will be made aware of this at remote consultation supported by 
documentation by letter. 
Judicious use of investigations which require face to face appointments, providing a 
diagnosis but which do not change the treatment plan will be practiced e.g. use of tubal 
patency test for determining cause of infertility or repeat sperm tests.  
 
After discussion a flow chart has been agreed, if there is a delay in cervical screening 
(Appendix 3)  
 
Consents  
Due to stringent regulations, fertility services need several complex consent forms to be 
signed prior to commencing any treatment. This has been traditionally done face to face in 
long appointments.  
Online electronic consents specific for fertility treatments are now available, which meet 
regulatory requirements. They can be completed by patients in their own time and space. 
Their progress and consent documents can be checked remotely by clinic staff. Clinics are 
already using it in other devolved nations.   
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We aim to work collectively across Scotland along with the Government and NSD to procure 
the dedicated package as soon as possible. This will save time for clinic staff, reduce face to 
face appointments for patients and will meet regulatory requirements in a realistic manner in 
addition to being cost effective in long term.  An initial meeting with representative of all 4 
centers, NSD, SG and procurement was held on 12/05/2020. Further meetings are set up to 
take this forward. 
 
Use of electronic records 
Wherever possible electronic records and communication will be used, as paper and physical 
records have risk of transmitting infection. Witnessing is important step throughout all fertility 
treatments.   
 
Safer regimens  
Fertility treatments use hormonal medications which have a risk of ovarian hyperstimulation 
(OHSS). We already use regimens and practices which minimise the risk of OHSS e.g. use 
of antagonist regimens, GnRHagonist for trigger and low threshold for electively freezing all 
embryos in those at high risk of OHSS. Empirical immunosuppressants are not used in 
Scotland.  
We will continue to follow the multiple birth minimisation strategy to reduce the risk of multiple 
pregnancy to keep it to lowest in line with professional and regulatory bodies advice. Anyone 
at high risk of multiple pregnancy (e.g. young women with good quality embryos) should not 
have double embryo transfer to reduce the burden on NHS further in line with Government  
and health board advice (https://fertilitynetworkuk.org/trying-to-conceive/fertility-treatment/fertility-
treatment-options/single-embryo-transfer/). 
As per guidance issued by BFS/ ARCS, we will agree on a Scotland wide protocol for use of 
antibiotics in procedures. 
Wherever possible protocols will be modified to reduce face to face monitoring requirements, 
without compromising success rates of the treatments. 
Procedures including AGPs will only be performed where strictly necessary and will be 
avoided where there is a risk of COVID-19. Consideration to alternatives (local or regional 
anaesthesia, conscious sedation, deferment) will be made and if alternatives are not 
available consideration given to screening patients beforehand. It is not expected that AGP 
will form a routine part of most fertility centres work. Any individual cases will be discussed in 
multidisciplinary team if there is a requirement for AGP.  
 
Consent to go ahead with treatment  
Although fertility treatment may start, in the current scenario, all patients will be given 
a choice of deferring treatment for 6 months without compromising their position on 
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waiting list (Appendix 1).  The 6 months will start from the point that their clinic 
contacts them with an offer of treatment.   Those who chose to defer, must contact 
their clinic within these 6 months with a view to start treatment.  
They would need to actively consent, prior to having any fertility treatment whilst there 
is a risk that they could contract COVID-19 either during the treatment or if successful, 
during pregnancy or following delivery. This will be regularly reviewed.   
 
 
Scheduling of procedures 
 
Planning will be done to minimise staff working at various workstations/ procedure rooms 
especially in the laboratory and in the sharing of equipment as much as possible. Working 
patterns of staff will be reconfigured to minimize interaction between staff and reduce the 
number of personnel present within the service at a given time. This will be carefully 
balanced to ensure that there are appropriate levels of staff to safely carry out clinical activity. 
This may require working in smaller teams, extending the working day, compression of hours 
and spreading the work force across a 7-day working model. When planning staff rosters, the 
appropriate skill mix will be maintained and staff working towards HCPC registration, the 
certificate of completion of training will continue to be supervised and supported in 
undertaking laboratory and clinical procedures.   Developing new flexible working patterns 
will take cognisance of the fact that it may be easier for some staff to work flexibly than 
others. This will need to include Human Resources team locally and Partnership 
engagement. In making all decisions, considerations will be given to safety of staff and 
patients as well as ensuring continued suppression of virus. 
 
 
3.3 Specific issues for Laboratory  
 
Where deemed appropriate, the home production of semen samples for treatment will be 
considered as an effective way to reduce patient footfall and transmission.  
Infection control practices will also be reviewed and amended. This will include increased 
frequency of hand washing and use of appropriate PPE. The increased frequency of robust 
decontamination procedures which are not detrimental to gametes and embryos will be 
employed.   Waste management practices will be used to ensure clinical waste is being 
handled in a manner that will reduce risk of contamination, at the same time disposed of in a 
timely and sensitive manner.  
Any equipment which has been switched off will be monitored over a period of time to ensure 
it is fully functioning (FAQ Issued by HFEA 22/04/20).  All service maintenance of equipment 
will be undertaken as usual. Clinics will contact the main suppliers that supply laboratory 
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media and consumables to ensure there is likely to be enough availability of products and 
that the delivery will be unaffected due to increased demand from the clinics. The main 
suppliers of IVF products – Vitrolife, Cook, Cooper Surgical and Hunter – have all advised 
that there is plenty of availability of products and delivery time of products should be as 
normal.  
Currently, there is evidence, although limited, to support the presence of Coronavirus in 
gametes or embryos, therefore caution will be applied to the handling and processing of 
samples. It is too early to have data for risk of infection, transmission and persistence.  In 
cases where patients are symptomatic and tests results for COVID are awaited, closed 
systems or vapour phase storage will be considered to reduce the risk of cross contamination 
between samples and transferred to an appropriately screened/ confirmed positive storage 
tank once the results are known.  
 
3.4 Risk assessments at individual clinics  
 
Prior to resuming treatment, all procedures (including lab procedures) will be individually 
process mapped and risk assessed to identify where risk of transmission and infection can 
be safely reduced without negatively impacting treatment outcome.  
While most decisions and practices will be agreed at Scottish level, there will be individual 
variations in clinic practices depending on space and staffing availability. Hence individual 
risk assessments will be required by clinics for each area of working practices including office 
space, waiting areas, templates for clinic appointments, procedures, recovery area, access to 
sperm production rooms, practices within the laboratories to ensure social distancing etc.  
Although done individually, the risk assessments will be shared amongst various clinics to 
ensure sharing of good clinical practices and work more collectively.  
 
3.5 Start date  
 
On the 1st of May 2020, the HFEA announced that fertility clinics will be able to apply to 
reopen once a revision to GD0014 has been issued. The HFEA have indicated that the 
revised GD0014 will be issued the week beginning the 11th of May, with applications to 
commence treatment to be submitted thereafter. The process for applying to reopen is 
dependent on completion and approval of the HFEA COVID-19 Treatment Commencement 
self-assessment tool. Processing is expected to take 5 working days from submission. 
Written approval from the centre Inspector must be received prior to resumption of 
treatments. In addition to fulfilling HFEÀ s requirement, Scottish clinics will need 
permission from Scottish Government as well as local health boards before resuming 
activity. At the same time consideration will be given to lockdown restrictions that 
currently are extended till end of May 2020. Travel will be for medical reasons only. 
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All NHS clinics in Scotland have agreed on a single date (18/05/2020), in agreement with 
Scottish Government, for application to HFEA to lift General Direction 00014. It is anticipated 
that the type of treatments prioritised may differ in clinics in the beginning, but all clinics will 
be able to provide all treatments eventually. 
This is because fertility treatments are not done in isolation and require support from other 
specialties within hospital. A phased and measured introduction of treatment will be required 
to facilitate safe practice and patient treatment while allowing time to review and improve 
upon changes which have been made to routine practice during the COVID-19 pandemic.  
Careful planning will be required to determine the number of treatment cycles and the 
different types of treatment types that can be safely processed through the laboratory and 
clinical area while observing social distancing practices. Timing of clinical procedures will be 
optimised to ensure scheduling which will reduce risk to patients and staff and to allow safe 
workflow within the clinic without compromising success rates.  
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4 Working together for Scotland  
 
4.1 Equity of treatment 
 
In order to provide equitable services across Scotland we will prioritise NHS funded 
treatments across all 4 centres to treat NHS funded patients. There will be no transfer of 
funding to private centres, even if there was a request for the possibility of earlier treatment. 
All centres will maximise their capacity by working efficiently to get through waiting lists. 
However, this will need to be done safely and cautiously taking into considerations of the 
principles outlined in section 2. 
 
4.2 Communication  
 
At all times communication will be key in managing this unprecedented clinical situation. We 
will communicate between clinics, within clinics, with primary care colleagues, patients and 
professional organisations such as HFEA, BFS, ARCS as well as colleagues in other parts of 
the world, who have already restarted treatments. We will work closely with Fertility network 
UK (the UK’s leading fertility patient organisation) throughout our discussion. 




4.3 Prioritisation of treatments  
 
We are aware that waiting lists will be long and many patients would wish to have treatment 
as soon as possible. All clinics have been keeping lists of those who could not complete 
treatment and those who could not start, in addition to keeping a list of those on waiting list. 
It is uncertain at present times as to whether we should treat everyone in order of waiting list 
or prioritise those with low ovarian reserve or start with those who have embryos frozen.  Any 
decisions will need to take in considerations as outlined in section 2. 
During the meeting on 28/04/20, the group agreed that there were benefits in starting 
treatments for those with embryos frozen as: 
 This does not pose risk of ovarian hyperstimulation (which may need unpredictable 
hospital admission and sometimes multiorgan dysfunction and ITU admission)  
 It is simple, safe relatively non-invasive treatment and easy to start and stop, if we 
need to, in event of second wave of COVID-19 and further lockdown. 
 It allows for all staff to adapt to new ways of working and refresh skills 
 It does not require sedation, oxygen or anaesthetists, who may be required elsewhere  
 
Evidence up until now suggest that COVID-19 does not have significant impact on 
pregnancy. However, we have to be mindful that this is new disease and evidence is 
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continuously evolving, both in terms of data relating to disease symptoms, impact on body 
systems and long term sequelae. We will continue to monitor evidence on pregnancy and 
COVID19 as it is evolving7. Pragmatic decision based on robust clinical data will be made 
and modified as clinical and scientific data are available.  
 
In making decisions we will be conscious that fertility treatments involve multiple 
appointments at hospital i.e. travel, although travel is for medical need but poses risk in 
current climate. This poses real risk to those who have to travel long distance as treatments 
are provided in Aberdeen, Dundee, Edinburgh and Glasgow only. At all times considerations 
will be given to equity, parity, as well as logistics of delivering a safe service alongside patient 
wishes. 
We are aware of the potential need to suddenly stop treatments in the event of a second 
wave. 
Diagnostic services may be started first (e.g. semen analysis and Hydro-contrast sono-
salphingography) followed by treatments.  This will give a chance for some of the process to 
be rehearsed and modified before actual treatment start. 
We will apply particular caution to patients with underlying medical problems whose co-
morbidity places them at a higher risk of complications in the event of contracting coronavirus 
infection. This includes patients with hypertension, diabetes, severe asthma and those 
receiving immunosuppressive medication. It may be appropriate for such patients to delay 
conception until epidemiological evidence shows a sustained reduction in the community 
spread of the infection. These will be discussed as part of multidisciplinary group for 
individualised decision making.  
If a patient had COVID -19 which required respiratory support, we will liaise with relevant 
clinicians. Treatment will only be commenced once a favourable assessment is obtained.  
We will work with evolving scientific and medical evidence to prioritise fertility treatment and 
develop a joint approach which will be transparent and uniform across Scotland.   
 
A Road map has been agreed (Appendix 4) after multiple discussion within the group. 
 
 
4.4 Access to NHS treatment 
 
The group is aware that there are patients who could not start treatment despite being near 
or at the top of the waiting list, others could not complete or initiate a subsequent cycle of 
treatment, while others are waiting for initial referral.  
As one of the main access criteria to NHS treatment is based on age of female partner, many 
fear losing access to NHS funded treatment due to delays imposed by COVID-19, and others 
may not be able to access their full potential entitlement.  
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In order to be fair, equitable and ethical, it was agreed that those who are already on waiting 
list will have this time paused and extra months from 17/03/20 – to whenever the clinics can 
open (and contact individual patient to offer fresh IVF treatments) will be added to their 
access for their full treatment journey, as long as other NHS criteria of are met.  This is the 
case both for couples where the partner being treated is under 40 and couples where the 
partner being treated is aged between 40 and 42. 
 
All those who are referred from primary and secondary care during the pandemic time ( 
01/03/20 - 31/08/2020), will have 6 months added  to age eligibility criteria,  so that couples, 
especially where the woman/partner having treatment is older, are not disadvantaged in 
accessing either one full cycle or three full cycles, if it is clinically appropriate to do so.   This 
takes into consideration that there have been delays in referrals for treatment, both at 
primary and secondary care. We are also aware that patients have not approached GPs for 
referral due to the pandemic.  
 
However, all clinics will be working with remote consultations to address these referrals as 
soon as it is feasible and safe. 
 
Frequently asked questions (FAQs) to patients, which will be put on webpages of all clinics 
and Fertility Network UK, to provide clarity regarding management of the waiting list so that is 






5 Support  
 
5.1 Support for patients  
 
Counsellors are an integral part of the treatment and support offered by the clinics as per 
regulatory requirements. Counselling will be offered remotely using telephone appointments 
or systems e.g. attend anywhere, near me, which will significantly reduce the number of face-
to -face appointments, hospital attendances and staff-patient contact time. Information about 
counselling will be made available on webpages of all clinics. 
There is work being undertaken to develop online/video psychosocial educational groups as 
well as possible support groups. As a result of welfare of the child considerations or case 
complexity, on occasion face to face counselling or assessment may still be required in the 
medium term. 
We plan to host Webinars for patients instead of face to face patient information evenings 
(PIE) that are usually attended by multiple patients together, to keep the interaction and be 
able to answer the queries.  We also aspire to do sessions for patients for specific causes of 
infertility e.g. male factor, endometriosis etc. using online platform, jointly across Scotland.  
This will not only maximise the use of resources but will help in providing consistent 
information to patients across Scotland. 
All clinics will ensure support for patients by increasing the capacity to answer queries via 
telephone and emails. In addition to sharing the good practices, clinics will share any online 
resources so that there is no duplication of efforts e.g. no delays by NHSG.  
As part of information during the treatment patients will be advised that other services in NHS 
e.g. Early Pregnancy Assessment Units may have different policies during COVID-19.  
 
Patients have already been advised through communication put on the website that clinics 
are not open yet but can apply to open in the week beginning 11th May. Clinics will be in 
touch with patients on the waiting lists as soon as they can proceed with treatments safely. 
Prior to any treatment patients will be provided with information relating to the risk of Covid-
19 by coming to hospital, in pregnancy and be offered the choice to defer treatment by 
signing the consent form (Appendix 1). 
 
Fertility Network is the leading patient-focused fertility charity and provides free and impartial 
support as well as advice at practical and emotional level to improve information and 
understanding.  Patients have access to a support line manned by a retired fertility nurse and 
a community of people affected by fertility problems at https://fertilitynetworkuk.org/   or  




Patients can also access more information from following webpages 
 
 HFEA COVID-19 guidance for patients  
 British Infertility Counselling Association  









5.2 Support for Staff  
 
As there will be a number of significant changes in the ways of working, clinic leads will 
ensure communication within their own multi-disciplinary teams. This is especially important 
as many staff have been redeployed. They will need to be recalled, when safe and feasible to 
do so. There will be a period of retraining, mock drills and refining the process to ensure that 
new ways of working are feasible and are abiding by the principles outlined in section 2. 
Good practices will be shared across all clinics in regular weekly meetings.   Staff support 
policies and procedures will be in place in each clinic to ensure that: 
- The mental well-being of staff is considered and reviewed as necessary 
- Staff support and counselling systems are in place should they be needed 
- Staff continue to be engaged and encouraged to provide feedback on progress and 
potential improvements to treatments during the COVID-19 pandemic 
- Peer support is available as needed 
- Staff safety in the workplace is paramount and centres should ensure that risk assessments 
are in place where appropriate to minimise the risk of infection 
There are individual health board web pages e.g.  
https://covid19.nhsgrampian.org/for-nhs-grampian-staff/   
http://intranet.lothian.scot.nhs.uk/StaffRoom/StaffHealthAndWellbeing/Pages/default.aspx  
https://www.nhsggc.org.uk/your-health/health-issues/covid-19-coronavirus/ 
There was also support amongst group to share the staff continuous professional 
development (CPD) sessions as they will now all be done remotely. This will not only 
enhance communication but will reduce the variability of practices across Scotland. 
 
5.3 Code of conduct for Staff  
 
All staff members will be asked to read and sign a code of conduct when clinics reopen, as 
required by HFEA (Covid -19 Self-assessment questions 11,12,13) as a prerequisite to grant 
permission to provide licenced treatments. This will instruct to avoid unnecessary exposure 
(both at work and in private) as per current government policies for social distancing.  This 
will be emphasised in team briefs. Attendance at work will be tied to respecting this Code of 
Conduct. Staff members will inform their line manager of any infringements of the Code of 
Conduct previously signed.   
If triage questionnaire (e.g. in Appendix 2) is completed, answering Yes to any question in 
the questionnaire, staff may be advised isolation/testing as per local policy advised by Public 
Health Scotland.  In addition to following Government guidance, Staff who are shielding or 
who live with someone who is shielding, will not be involved in care of patients. 
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5.4 Code of conduct for Patients  
 
All patients will be instructed to sign a consent prior to commencing any treatment, which will 
incorporate the code of conduct to avoid unnecessary exposure (both at work and in private) 
as per current government policies for social distancing.  The triage questionnaire (Appendix 
2) will be filled in 2 weeks prior to commencing treatment and will be confirmed at each 
interaction.   
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6 Uncertainties  
 
 
6.1 Testing strategies  
 
Although European (ESHRE) guidance provides a good framework for creating a COVID-19 
free environment in fertility clinics, the testing strategies they advise are not approved in the 
Scotland yet. In addition, there are still uncertainties about sensitivity, specificity and 
availability of various tests especially in asymptomatic patients. 
https://www.gov.scot/publications/coronavirus -covid-19-getting-tested/pages/overview/ 
It is important for consistency that all clinics are following similar protocols, hence further 
guidance from virology was sought.. 
We  liaised with the Clinical Lab/Virology Cell in Health Protection Scotland for further advice 
on guidance for Fertility treatment and COVID-19 testing.  We propose the flow chart as in 








































Figure 1: Flow chart for test and decision making  
 
 
If pre-test probability9    is high, treatment will be cancelled irrespective of the test. 
 
The time point of testing prior to OR (oocyte retrieval) is taken in line with other pre operative 
testing. Testing will be requested at last monitoring USG, which is approximately 40-48 hours 
prior to the procedure. 
 
Patients (as per consent) will be asked to follow government guidance for isolation 
preoperatively during the course of treatment, 
 
There will be no financial implications/ full access to NHS funded treatment if the 
treatments are cancelled due to COVID-19.  
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6.2 Use of Personal protective equipment 
 
Safe distancing will be practiced wherever possible. It is accepted that some processes (e.g. 
diagnostic, operative and laboratory work) will require working within close proximity to 
colleagues.  Although most procedures are not aerosol generating, appropriate PPE 
(https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-
and-control/covid-19-personal-protective-equipment-ppe)  and application of infection control 
measures will be required for each area to reduce the risk of infection. 
A suggested guidance for PPE for specific processes in fertility treatment is given in Table 5. 
Securing PPE will be a challenge when we are competing with other specialties.  
 














surgical mask  
Eye/face 
protection  
            
Reception        sessional use   
patients        single use   
Examination / USG/ 
HyCoSy   single use  single use   sessional use   
venepuncture   single use  single use   sessional use   
Egg collection  
(operator)   single use   Single use sessional use 
sessional 
use 
Egg collection (other 
staff in room)   single use  single use   sessional use   
ET/IUI   single use  single use    sessional use   
Andrology lab  single use  single use    sessional use  
Embryology lab   single use  single use    sessional use  
 
Use non embryo/gamete toxic cleaning material for clean room and egg collection/ embryo 





6.3 Second wave  
 
Although the current lockdown may ease, we recognise that there is a possibility of second 
wave especially during winter flu season, and thus a possibility of restrictions being re-
imposed. Although it is not possible to predict timing and/or duration, this may cause further 
impact on provision of fertility services, which will need to be factored in, to decision making 





7 Review of Strategy  
 
Regular review of any decision making will be done by initially weekly meetings through ms 
teams. It is anticipated that the strategy will evolve as more evidence and experience comes. 
 
This will then potentially lead to changes in protocols at both national and local level to 
provide more effective care by efficient use of resources.  
 
At all times this will be collective decision across Scotland using a multidisciplinary approach. 
 


















Association of Reproductive and Clinical Scientists 
AGP 
 
Aerosol Generating Procedure 
BFS 
 
British Fertility Society  
COVID-19 
 
Corona Virus Disease 2019 
ESHRE 
 






Frozen Embryo Transfer 
FFP3 
 
Filtering Face Piece Mask 3 
HCG 
 
Human Chorionic Gonadotrophin  
HFEA 
 
Human Fertilisation and Embryology Authority 
HyCoSy 
 
Hydrocontrast Sono-salpingography  
ITU  
 
Intensive Treatment Unit  
NHSG  
 
NHS Grampian  
PR 
 
Person Responsible  

































5. https://www.gov.scot/publications/coronavirus -covid-19-framework-decision-making/ 
 
6. Marcos Meseguer, Craig Niederberger, Antonio Pellicer  Deep inside the pandemic, 
from inactivity to action: let’s be ready.  Publication stage: In Press Journal Pre-Proof 








9. BMJ 2020; 369 doi: https://doi.org/10.1136/bmj.m1808 (Published 12 May 2020) Cite this 











10 Membership of the group  
 
 
Fertility Network UK  
Gwenda Burns – Chief Executive  
 
Aberdeen 
Alison McTavish, Unit Manager and Licence holder  
Abha Maheshwari, Lead Clinician and Person Responsible  
Elizabeth Ferguson, Laboratory Manager  
 
Dundee 
Sarah Martins da Silva, Consultant Gynecologist and Person Responsible  
Suresh Kini, Consultant Gynecologist 
 
Edinburgh 
Joo Thong, Lead Clinician and Person Responsible  
Dave Wales, Quality Manager  
 
Glasgow  
Helen Lyall, Lead Clinician  
Joanne Leitch, Person Responsible 
Scott Nelson, Professor of Obstetrics & Gynaecology, Nominal HFEA license holder 
Michelle Mclauchlan, General Manager, Obstetrics and Gynaecology 
Isobel Traynor, Lead Nurse Assisted Conception & Gynaecology 
 
Scottish Government  
Sarah Corcoran, Team Leader, Maternal and Infant Health 
Louise McCue, Senior Policy Manager, Maternal and Infant Health Team 
 
NSD 





















11 Appendix 1 
 







You are currently on the waiting list for fertility treatment. Following regulatory approvals, we 
are now in position to be able to offer you treatment. As per current evidence there does not 
appear to be an increased risk of miscarriage, risk of pregnancy complications or any effect 
on the baby. However, you need to be aware that the data is limited, and this may change as 
we continue to gather information.  Provision of treatment will however require you to attend 
hospital which will incur a small risk of viral transmission as compared to social isolating at 
home. Comprehensive procedures are in place to minimise this risk for all patients.  
 
Please contact us on XXXX  to inform us whether you wish to proceed with treatment 
or remain on the waiting list at this time. We will then be able to provide you with a 
date to discuss next steps.  
 
If you would rather not attend hospital during this time then you will remain on the waiting list 





12 Appendix 2 
 
 




1. Have YOU or YOUR PARTNER or ANY MEMBER OF YOUR HOUSEHOLD been 
diagnosed with Covid-19? ( not for staff questionnaire) 
2. Have YOU or YOUR PARTNER or ANY MEMBER OF YOUR HOUSEHOLD had any 
of the following symptoms in the last 2 weeks 
 Fever (feeling hot or a temperature above 37.8 degrees Celsius) 
 Persistent cough 
 Loss of the sense of smell 
 Loss of the sense of taste 
 Sore throat 
3. Have YOU been in contact with anyone in the last 2 weeks who has any of these 
symptoms or has been diagnosed with Covid-19? 
4. Have you travelled abroad recently?  
5. Have YOU or YOUR PARTNER been asked by NHS Scotland to shield? 
6. Do you have a severe medical condition like diabetes, respiratory disease, chronic 
































Ready for fertility 
treatment 
cervical screening up to 
date prior to lockdown
Previous normal result
Fertility Treatment can 
proceed *
(if no clinical concern )
HPV +, borderline or low 
grade
delayed repeat cervical 
screening  or colp 
assessment due to lockdown
Do not proceed
Assessed at colposcopy-
now within current low grade follow up 
pathway with  no imminent  treatment 
required**
Fertility treatment can proceed 
Previous colposcopy 
treatment
Delayed test of cure cervical 
screening due to lock down 
Await test of cure result.
Do not proceed with fertility 
treatment
Cervical screening 
delayed due to Covid 
N.B.  Primary HPV cervical screening 
commenced in March 2020 as planned.  This 
will subsequently alter the screening interval 
from 3 to 5 years (for those on routine recall). 
 
29 
* Inform patient that exception has been to usual protocols due to time sensitive manner of their fertility treatment – if patient accepting of 
this and not able to have cervical screening obtained by local team prior to commencing treatment, then the overdue screening test 
should be obtained at next available opportunity e.g. postnatal or between cycles.  
 
** Consider discussion with local colposcopy team if scheduled repeat colp assessment/cervical screening due < 3months. 
As previously - any patient with an unresolved high grade cervical screening test result, suspicious cervix/symptoms or awaiting a 






14 Appendix 4 – Road map  
 
 Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 
Treatments that can 
be done  
 





Frozen embryo transfer  
 
Donor insemination (DI)  





 Treatment for only 
those without 
comorbidities 
In addition to phase 1 
 
Start of stimulation in older 
women (≥ 40 years) 
 
 
Ovulation Induction (oral) 
 
 
Treatment for only those 
without comorbidities 
In addition to phase 2 
 
Ovulation Induction  
(injectables) 
 
DI   with stimulation  
 
Start of stimulation in 
younger women  
 
 
Treatment for only those 
without comorbidities 









Treatment in those with 
co morbidities  





Donor recruitment  
 
 
Conditions to be 
satisfied to move to 
next phase 
 
Easing of lockdown 
restrictions progressing 
as planned 
No further suspension of 
activity by HFEA 
 
No evidence of 
detrimental effect of 
Pregnancy on Covid and 
vice versa 
 
In addition to requirements in 
phase 1 
 
Low incidence of OHSS  
 
Staff returning from deployed 
areas as planned  
 
 
In addition to requirement 
in phase 2 
 
 
Low incidence of OHSS  
 
In addition to requirement 
in phase 3 
 
 
Full staff complement  
 
Social distancing rules 
relaxed  
Full resumption of all 
services back to pre -
Covid state 
Conditions to step to 
previous phase  
Government Ease down 





Not adequate staff (either 
deployed/ self- isolation) 
Government Ease down 





Not adequate staff  
(either deployed/ self- 
isolation) 
Government Ease down 





Not adequate staff 
 (either deployed/ self- 
isolation) 
Government Ease down 





Not adequate staff 




Assumptions for Road map  
 
 Emergency fertility preservation will continue throughout, this include sperm cryo 
preservation when immediate IVF/ICSI not possible, and sperm count declining  
 Moving in phases is not dependent on testing strategies as that will be covered in 
Government policies 
 Diagnostic means semen analysis (which all centres may not wish to proceed) and 
HyCoSy and USG as that will be required prior to DI and other treatments 
 Those waiting for surgery (due to any reason) will need to wait for NHS theatre lists 
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